Pricing Log in Create free account
Friday 6 November 2026 Export IFF’s income statement to Excel — free account

International Flavors & Fragrances Inc.

IFF Basic Materials Specialty Chemicals

Revenue
+3.91%
EPS
−235.9%
Free cash flow
−123.3%
Total debt
+32.3%

Quarter to September 2026, against a year earlier

83.54 2.82 −3.27%
Market cap
$21.6B
P/E
121×
Fwd P/E
60.3×
Dividend yield
1.85%
F-score
6/9
Altman Z
1.18
Beneish M
−2.54
Dividend safety
0/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

International Flavors & Fragrances Inc. 10-Q filed Nov 4, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 4:36 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2025: 21 added · 20 removed · 42 modified; 19 with only figures updated; 1 moved without change

  1. Modified · Company Background

    Our Pharma Solutions segment produced, among other things, a vast portfolio of cellulosics and seaweed-based pharmaceutical excipients, used to improve the functionality and delivery of active pharmaceutical ingredients, including controlled or modified drug release formulations, and enabling the development of more effective pharmaceutical finished dosage formulations. Our excipients are used in prescription and over-the-counter pharmaceuticals and dietary supplements. Our Pharma Solutions products also serve a variety of other specialty and industrial end-uses including coatings, inks, electronics, agriculture and consumer products. During March 2024, we announced the sale process and entered into an agreement to sell the Pharma Solutions business disposal group, that is primarily made up of most businesses within the Company’s existing Pharma Solutions reportable segment. The transaction closed on May 1, 2025. During October 2024, we entered into an agreement to sell the Nitrocellulose disposal group, which iswas within our existing Pharma Solutions reportable operating segment. The transaction closed on May 9, 2025. See Note 3 for additional information. As of June 30May 9, 2025, there is no remaining business in the Pharma Solutions reportable operating segment.